Natco Pharma has submitted a copy of Press Release dated August 25, 2016 titled ‘NATCOs marketing partner Mylan Invalidates Two of Tevas Copaxone 40 mg/mL Patents Via US Patent and Trademark Offices Inter Partes Review Proceeding’.
The above information is a part of company’s filings submitted to BSE.